Market Cap€68m

Last Close €18.44

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

More SynBiotic content >

Investment summary

SynBiotic has announced it is acquiring 50.1% of the shares of several market-leading hemp companies, which are part of hemp industry pioneer Daniel Kruse’s group of companies. There will be a capital increase in kind to fund these acquisitions and €2m in cash will be contributed to the capital reserves of the companies being acquired. This marks another step in SynBiotic’s buy-and-build strategy, whereby management is using its experience in scaling profitable companies to accelerate SynBiotic’s strategy to be a leading platform company in the cannabinoid industry.

Content on SynBiotic
SynBiotic – Further acquisitions
Consumer | research Update | 6 December 2021
Cannabis leaf with magnifying glass
SynBiotic – Building a cannabis platform
Consumer | research QuickView | 1 November 2021
Cannabis leaf with magnifying glass
SynBiotic – Working together
Consumer | research Initiation | 29 July 2021
Cannabis leaf with magnifying glass
View more
Register to receive research on SynBiotic as it is published
Share price graph
Price performance
Actual (1.1) (5.4) (17.2)
Relative* (1.3) (2.4) (9.8)
52-week high/low €40.4/€16.7
*% relative to local index